ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Jemincare and Shanghai Jeyou Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

JemincareShanghai Jeyou Pharmaceutical
studies on the registry373
open to participants now303
phase 3 studies under way31
reach primary completion within a year61
programswith a study of their own in two years94

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJemincareShanghai Jeyou Pharmaceutical
Phase 1

Jemincare: 5 of its 9 programs at phase 1

  1. JMKX000197phase 1
  2. JMKX003948phase 1
  3. Amiodaronephase 1
  4. JMKX005425phase 1
  5. JY1001phase 1
56%

Shanghai Jeyou Pharmaceutical: 1 of its 4 programs at phase 1

  1. JMKX000189phase 1
25%
Phase 200%

Shanghai Jeyou Pharmaceutical: 1 of its 4 programs at phase 2

  1. JMKX000197phase 2
25%
Phase 3

Jemincare: 3 of its 9 programs at phase 3

  1. JMKX003142phase 3
  2. ozureprubartphase 3
  3. KRAS G12C Inhibitor JMKX001899phase 3
33%

Shanghai Jeyou Pharmaceutical: 2 of its 4 programs at phase 3

  1. ifebemtinibphase 3
  2. sosimerasibphase 3
50%
Approved, new studies

Jemincare: 1 of its 9 programs at approved, new studies

  1. sonidegibapproved, new study
11%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Jemincare3 readouts · 1 phase 3···

Jemincare, Feb ’27: 1 program whose next study reaches primary completion

  1. JMKX003142phase 3 · Feb 28 · NCT06800651
··

Jemincare, May ’27: 1 program whose next study reaches primary completion

  1. JY1001phase 1 · May 0 · NCT07848945

Jemincare, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. ozureprubartphase 3 · Jun 7 · NCT07402213
····
Shanghai Jeyou Pharmaceutical1 readouts · 0 phase 3·······

Shanghai Jeyou Pharmaceutical, Jun ’27: 1 program whose next study reaches primary completion

  1. JMKX000189phase 1 · Jun 20 · NCT07601386
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Jemincare

New programs 1

  • JY1001phase 1 · first study · Sep 17 · Pain

Reached a new phase 1

  • JMKX003142phase 3 · Sep 7 · Polycystic Kidney, Autosomal Dominant

Study stopped 0

None

Primary completion later 0

None

Shanghai Jeyou Pharmaceutical

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionJemincareShanghai Jeyou Pharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

Jemincare in Carcinoma, Non-Small-Cell Lung: 1 program

  1. KRAS G12C Inhibitor JMKX001899phase 3

Their studies: Jemincare’s studies of Carcinoma, Non-Small-Cell Lung in search

Shanghai Jeyou Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. ifebemtinibphase 3

Their studies: Shanghai Jeyou Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Pancreatic Neoplasmsboth · compare here

Jemincare in Pancreatic Neoplasms: 1 program

  1. sonidegibapproved, new study

Their studies: Jemincare’s studies of Pancreatic Neoplasms in search

Shanghai Jeyou Pharmaceutical in Pancreatic Neoplasms: 1 program

  1. ifebemtinibphase 3

Their studies: Shanghai Jeyou Pharmaceutical’s studies of Pancreatic Neoplasms in search

Pleural Effusion, Malignantboth · compare here

Jemincare in Pleural Effusion, Malignant: 1 program

  1. JMKX000197phase 1

Their studies: Jemincare’s studies of Pleural Effusion, Malignant in search

Shanghai Jeyou Pharmaceutical in Pleural Effusion, Malignant: 1 program

  1. JMKX000197phase 2

Their studies: Shanghai Jeyou Pharmaceutical’s studies of Pleural Effusion, Malignant in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Jemincare 4 of 9 · Shanghai Jeyou Pharmaceutical 1 of 4 programs (5 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.